There are 3397 resources available
Conclusions and perspectives
Presenter: David Spiegel
Session: Protein degrading cancer drugs: The promises of the new generation
Resources:
Webcast
Invited Discussant LBA70 and LBA71
Presenter: Yi-Long Wu
Session: Mini oral session 1 - NSCLC, metastatic
Resources:
Slides
Webcast
1312MO - Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: Overall survival data from the first line non-small cell lung carcinoma (NSCLC) cohort of TACTI-002 (phase II)
Presenter: Enric Carcereny
Session: Mini oral session 1 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
Conclusions and perspectives
Presenter: Ruth Plummer
Session: New targets on the horizon
Resources:
Slides
Webcast
Invited Discussant 2360O and LBA103
Presenter: Thomas Powles
Session: Proffered Paper session 1 - Genitourinary tumours, non-prostate
Resources:
Slides
Webcast
Conclusions and perspectives
Presenter: Ignacio Melero
Session: Advancing strategies for cancer immunotherapy
Resources:
Slides
Webcast
Conclusions and perspectives
Presenter: Jean Yannis Perentes
Session: Open questions in the management of mesothelioma
Resources:
Webcast
Conclusions and perspectives
Presenter: Thorsten Zenz
Session: Next generation diagnostics of blood cancer: An optimistic view on the future of cancer testing
Resources:
Webcast
1313MO - Safety and preliminary efficacy of AZD7789, a bispecific antibody targeting PD-1 and TIM-3, in patients (pts) with stage IIIB–IV non-small-cell lung cancer (NSCLC) with previous anti-PD-(L)1 therapy
Presenter: Benjamin Besse
Session: Mini oral session 1 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session 1 - Genitourinary tumours, non-prostate
Resources:
Webcast